David A. Siegel Acadia Pharmaceuticals Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 484,300 shares of ACAD stock, worth $8.08 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

484,300

Previous 55,400 774.19%

Holding current value

$8.08 Million

Previous $900,000 728.11%

% of portfolio

0.02%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.14 - $19.14 $6.49 Million - $8.21 Million	428,900 Added 774.19%	484,300 $7.45 Million
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $488,308 - $615,228	33,400 Added 151.82%	55,400 $900,000
Q1 2024 May 15, 2024	SELL	$17.79 - $30.86 $846,804 - $1.47 Million	-47,600 Reduced 68.39%	22,000 $406,000
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $1.06 Million - $1.62 Million	50,900 Added 272.19%	69,600 $2.18 Million
Q3 2023 Nov 14, 2023	SELL	$20.84 - $33.47 $3.16 Million - $5.08 Million	-151,700 Reduced 89.03%	18,700 $389,000
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $2.81 Million - $4.06 Million	158,100 Added 1285.37%	170,400 $4.08 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $200,736 - $257,316	12,300 New	12,300 $231,000
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $524,303 - $1.1 Million	-40,300 Reduced 70.83%	16,600 $234,000
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $1.19 Million - $1.56 Million	56,900 New	56,900 $1.38 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $3.68 Million - $5.2 Million	-189,500 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$25.02 - $54.99 $5.83 Million - $12.8 Million	-233,100 Reduced 55.16%	189,500 $4.89 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $8.85 Million - $12.2 Million	-215,600 Reduced 33.78%	422,600 $22.6 Million
Q3 2020 Nov 16, 2020	BUY	$36.42 - $57.0 $8.67 Million - $13.6 Million	238,100 Added 59.51%	638,200 $26.3 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $13.3 Million - $17.8 Million	338,400 Added 548.46%	400,100 $19.4 Million
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $1.36 Million - $2.02 Million	-43,100 Reduced 41.13%	61,700 $2.61 Million
Q4 2019 Feb 14, 2020	SELL	$36.21 - $51.4 $90,525 - $128,500	-2,500 Reduced 2.33%	104,800 $4.48 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $799,920 - $1.58 Million	36,000 Added 50.49%	107,300 $3.86 Million
Q2 2019 Aug 14, 2019	SELL	$23.32 - $28.12 $41,976 - $50,616	-1,800 Reduced 2.46%	71,300 $1.91 Million
Q1 2019 May 15, 2019	BUY	$16.17 - $27.38 $300,762 - $509,268	18,600 Added 34.13%	73,100 $1.96 Million
Q4 2018 Feb 14, 2019	BUY	$14.32 - $22.92 $780,440 - $1.25 Million	54,500 New	54,500 $881,000

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.7B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account